Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Freiburgstr. 18, 3010, Bern, Switzerland.
Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, Switzerland.
Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2036-2046. doi: 10.1007/s00259-024-06646-5. Epub 2024 Feb 22.
High blood glucose (hBG) in patients undergoing [F]FDG PET/CT scans often results in rescheduling the examination, which may lead to clinical delay for the patient and decrease productivity for the department. The aim of this study was to evaluate whether long-axial field-of-view (LAFOV) PET/CT can minimize the effect of altered bio-distribution in hBG patients and is able to provide diagnostic image quality in hBG situations.
Oncologic patients with elevated blood glucose (≥ 8.0 mmol/l) and normal blood glucose (< 8.0 mmol/l, nBG) levels were matched for tumor entity, gender, age, and BMI. hBG patients were further subdivided into two groups (BG 8-11 mmol/l and BG > 11 mmol/l). Tracer uptake in the liver, muscle, and tumor was evaluated. Furthermore, image quality was compared between long acquisitions (ultra-high sensitivity mode, 360 s) on a LAFOV PET/CT and routine acquisitions equivalent to a short-axial field-of-view scanner (simulated (sSAFOV), obtained with high sensitivity mode, 120 s). Tumor-to-background ratio (TBR) and contrast-to-noise ratio (CNR) were used as the main image quality criteria.
Thirty-one hBG patients met the inclusion criteria and were matched with 31 nBG patients. Overall, liver uptake was significantly higher in hBG patients (SUV, 3.07 ± 0.41 vs. 2.37 ± 0.33; p = 0.03), and brain uptake was significantly lower (SUV, 7.58 ± 0.74 vs. 13.38 ± 3.94; p < 0.001), whereas muscle (shoulder/gluteal) uptake showed no statistically significant difference. Tumor uptake was lower in hBG patients, resulting in a significantly lower TBR in the hBG cohort (3.48 ± 0.74 vs. 5.29 ± 1.48, p < 0.001). CNR was higher in nBG compared to hBG patients (12.17 ± 4.86 vs. 23.31 ± 12.22, p < 0.001). However, subgroup analysis of nBG 8-11 mmol/l on sSAFOV PET/CT compared to hBG (> 11 mmol/l) patients examined with LAFOV PET/CT showed no statistical significant difference in CNR (19.84 ± 8.40 vs. 17.79 ± 9.3, p = 0.08).
While elevated blood glucose (> 11 mmol) negatively affected TBR and CNR in our cohort, the images from a LAFOV PET-scanner had comparable CNR to PET-images acquired from nBG patients using sSAFOV PET/CT. Therefore, we argue that oncologic patients with increased blood sugar levels might be imaged safely with LAFOV PET/CT when rescheduling is not feasible.
在进行 [F]FDG PET/CT 扫描的患者中,高血糖(hBG)通常会导致检查重新安排,这可能导致患者的临床延误和科室生产力下降。本研究的目的是评估长轴向视野(LAFOV)PET/CT 是否可以最小化 hBG 患者中改变的生物分布的影响,并能够在 hBG 情况下提供诊断图像质量。
选择血糖升高(≥8.0mmol/l)和正常血糖(<8.0mmol/l,nBG)水平的肿瘤患者进行匹配,匹配肿瘤实体、性别、年龄和 BMI。hBG 患者进一步分为两组(BG 8-11mmol/l 和 BG>11mmol/l)。评估肝脏、肌肉和肿瘤中的示踪剂摄取。此外,在 LAFOV PET/CT 上进行长采集(超高灵敏度模式,360s)与等效于短轴向视野扫描仪的常规采集(模拟(sSAFOV),采用高灵敏度模式,120s)之间比较图像质量。肿瘤与背景比(TBR)和对比噪声比(CNR)用作主要图像质量标准。
31 名 hBG 患者符合纳入标准,并与 31 名 nBG 患者匹配。总体而言,hBG 患者的肝脏摄取显着升高(SUV,3.07±0.41 与 2.37±0.33;p=0.03),而大脑摄取显着降低(SUV,7.58±0.74 与 13.38±3.94;p<0.001),而肌肉(肩部/臀肌)摄取没有统计学显着差异。hBG 患者的肿瘤摄取较低,导致 hBG 队列中的 TBR显着降低(3.48±0.74 与 5.29±1.48,p<0.001)。nBG 患者的 CNR 高于 hBG 患者(12.17±4.86 与 23.31±12.22,p<0.001)。然而,在 nBG 8-11mmol/l 亚组分析中,与 hBG(>11mmol/l)患者在 LAFOV PET/CT 上进行检查相比,sSAFOV PET/CT 上的 nBG 患者的 CNR 没有统计学显着差异(19.84±8.40 与 17.79±9.3,p=0.08)。
虽然高血糖(>11mmol)在我们的队列中对 TBR 和 CNR 产生负面影响,但来自 LAFOV PET 扫描仪的图像与使用 sSAFOV PET/CT 从 nBG 患者获得的 PET 图像具有可比的 CNR。因此,我们认为,当重新安排不可行时,患有高血糖水平的肿瘤患者可以安全地使用 LAFOV PET/CT 进行成像。